Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUO-O
2017-004632-11Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of durvalumab, olaparib and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Oct 2018; status: active.
02
Drugs
durvalumabolaparibbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2017-004632-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004632-11.